Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Moleculin reported positive interim data from the Phase 2/3 MIRACLE trial, showing Annamycin achieved Complete Remission (CR) rates of 36% and 43% versus 12% for the control arm in relapsed or refractory AML patients. Composite Complete Remission (CRc) rates reached 50% and 57% for the two Annamycin doses compared to 29% for control in this intent-to-treat population of 45 subjects.
Key figures
- Drug Name
- Annamycin
- Phase Of Trial
- Phase 2/3
- Interim n
- 45
- Cr control
- 12%
- Crc control
- 29%
- Enrollment part a
- 67 of 90
- Cr annamycin 190mg
- 43%
- Cr annamycin 230mg
- 36%
- Crc annamycin 190mg
- 50%
- Crc annamycin 230mg
- 57%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.